Use of a Melatonin Analogue for the Reduction of Intraocular Pressure

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention involves using agomelatine, a melatonin analogue, in pharmaceutical formulations to effectively lower intraocular pressure (IOP) in humans and animals. The method focuses on treating or preventing glaucoma (both hypertensive and normotensive types) and other diseases characterized by high IOP. Agomelatine can be administered topically (such as through eye drops), among other routes, and shows significant efficacy in reducing IOP over several hours with a favorable safety profile.

Use CasesContent extracted from patent full text and abstract with AI.

• Topical eye drops or eye washes containing agomelatine for treating patients with ocular hypertension or glaucoma.
• Preventative therapy in individuals at risk for developing glaucoma or diseases involving elevated IOP, such as diabetic retinopathy, uveitis, or ocular inflammation/infection.
• Veterinary ophthalmology use for animals susceptible to glaucoma or high IOP, such as dogs, cats, rabbits, or horses.
• Alternative or adjunct therapy for patients not responding well to conventional glaucoma medications or experiencing side effects.
• Development of multi-delivery pharmaceutical products (gel, cream, solution, spray) for personalized or specific ophthalmic care.

BenefitsContent extracted from patent full text and abstract with AI.

• Significantly reduces intraocular pressure by up to 21% for several hours after topical application, which helps prevent glaucoma progression and vision loss.
• Agomelatine is already known and commercially available with a favorable safety and tolerability profile.
• Offers an alternative to existing IOP-lowering drugs, some of which have notable side effects or are ineffective in certain patients.
• Multiple administration forms (eye drops, gels, sprays, etc.) enable patient-centric treatment options and potentially increased compliance.
• Potential to treat a range of eye diseases beyond classic glaucoma, including those secondary to inflammation, infection, or diabetes.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to the reduction of intraocular pressure by means of a melatonin analogue. The present invention describes a method for reducing intraocular pressure by administering a pharmaceutical formulation of the commercially available substance agomelatine, N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide, and/or pharmaceutically acceptable salts thereof. The present invention also claims the use of agomelatine and/or pharmaceutically acceptable salts thereof for the preparation of a drug intended for the treatment and/or prevention of hypertensive and/or normotensive glaucoma and/or diseases characterised by high intraocular pressure. Said drug is preferably administered by the topical route, optionally carried by liposomes, and can be presented in various pharmaceutical forms, such as solutions, suspensions, emulsions, eye drops, liquid drops, liquid washes, gels, creams, ointments, lotions and sprays.